EUCTR2007-002557-23-ES进行中（未招募）不适用
Estudio de fase I/II abierto con aumento de la dosis para investigar la seguridad y tolerabilidad de acadesina en pacientes con leucemia linfocítica crónica de células B
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •B-CLL patients with refractory or relapsed disease who have received either a fludarabine containing treatment regimen or an alkylating agent.
- •Diagnosis of B-CLL according to NCI Working Group Criteria.
- •Have an elevated B-cell count of = 5000/mm3.
- •Have a T-cell count = 200/mm3.
- •ECOG Performance Status < 2.
- •Have a life expectancy of at least 3 months.
- •Age > 18 years, of either gender.
- •Have given written informed consent, prior to any study related procedure not part of the patient’s normal medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who, in the opinion of the Investigator, need immediate treatment with proven chemotherapy and/or immunotherapy, and/or transplantation.
- •Have B-CLL with central nervous system involvement.
- •Have participated in any other investigational drug study or have undergone an experimental therapeutic procedure considered to potentially interfere with the study in the 30 days preceding Day 1.
- •Have received chemotherapy or radiotherapy treatment in the 30 days preceding Day 1.
- •Require use of drugs or substances which inhibit platelet aggregation during the 30 days prior to Day 1 or during the study. These include: ADP receptor inhibitors (ticlopidine, clopidogrel), aspirin and other NSAIDs including COX inhibitors (except COX-2-selective inhibitors), dipyridamole, phosphodiesterase inhibitors (cilostazol), calcium channel blockers such as nifedipine, xanthines (eg theophylline, aminophylline) and substances containing caffeine. Glycoprotein IIB/IIIA inhibitors, including abciximab, eptifibatide and tirofiban, are also contraindicated.
- •Require oral or parenteral steroids with the exception of inhaled steroids or low-dose oral steroids (<10mg prednisolone per day or equivalent) for an indication other than B-CLL.
- •Have a serious medical or psychiatric condition that could, in the Investigator’s opinion, potentially interfere with their treatment and/or participation in the study.
- •Have uncontrolled diabetes mellitus that requires insulin treatment or is not controlled on oral therapy.
- •Have a history of gout.
- •Have a serious concomitant disease including:
- •oSignificant cardiac disease - New York Heart Association Classes III or IV or have suffered a myocardial infarction in the last 6 months.
- •oChronic pulmonary obstructive disease with hypoxemia.
- •oClinically active auto-immune disease.
- •oActive infection such as tuberculosis, CMV (Cytomegalovirus).
- •Any secondary malignancy requiring active treatment (except hormonal therapy).
- •Have inadequate bone marrow reserve: neutrophils < 1.0 x 109/L, platelet count < 50 x 109/L (unsupported by transfusion), or coagulation abnormalities.
- •Have inadequate liver function: total bilirubin > 1.5 x upper limit of normal values (ULN), AST, ALT, or alkaline phosphatase > 2.5 x ULN.
- •Have inadequate renal function, defined by serum creatinine = 1.5 x ULN, unless creatinine clearance is measured and found to be at least 90 mL/min.
- •Have serum uric acid levels outside the normal range.
- •Females of childbearing potential who are unwilling to employ adequate means of contraception (hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) for the duration of the study and 30 days after the last acadesine administration.
- •Pregnant or lactating females.
- •Male patients who are not surgically sterile and who are unwilling to use a condom with spermicide for the duration of the study and for 3 months after the last acadesine administration.
- •Abuse of alcohol or other recreational drugs.
- •Known HIV or Hepatitis B (unless clearly due to vaccination) or C positive.
- •Known allergy to acadesine or any of its excipients.
- •Have undergone previous allogeneic stem cell transplant.
- •Transformation to Richter’s syndrome or other aggressive B-cell malignancy.
研究者
相似试验
进行中（未招募）
不适用
Estudio de fase II, abierto, con titulación de dosis de ACZ885 (anticuerpo monoclonal anti-IL-1ß humano) para evaluar la eficacia clínica, seguridad, farmacocinética y farmacodinámica en pacientes con mutaciones NALP3 - A2102EUCTR2004-002980-26-ESovartis Farmacéutica21
进行中（未招募）
不适用
Estudio de Fase II multicéntrico, abierto con dos fases para la evaluación preliminar de la eficacia y la seguridad de E 7389 en pacientes con cáncer de próstata avanzado o metastásico refractario a tratamiento hormonal, se realizara una estratificación en relación a la quimioterapia previaA Phase II Multicenter, Open Label, Two-Stage Design Study EvaluatingE7389 in Patients with Hormone Refractory Prostate Cancer withAdvanced and/or Metastatic Disease Stratified by Prior Chemotherapy. - E7389-G000-204EUCTR2005-004271-37-ESEisai Limited110
进行中（未招募）
1 期
Estudio abierto de extensión de fase 2 con conatumumab .A Phase 2 Open Label Extension Study of Conatumumab.diferentes tumores sólidos, incluyendo, entre otros, cáncer colorrectal (CCR), cáncer de pulmón de células no pequeñas (CPCNP), sarcoma de tejidos blandos (STB), linfoma no Hodgkin (LNH), cáncer de páncreas y cáncer de ovario. Different solid tumors, including, but not limited to, colorectal cancer (CRC), non small cell lung cancer(NSCLC), soft tissue sarcoma (STS), pancreatic cancer, and ovarian cancer and non-Hodgkins lymphoma(NHL).MedDRA version: 12.1Level: LLTClassification code 10007050Term: CancerEUCTR2010-022270-14-ESAmgen Inc12
进行中（未招募）
1 期
Etude de phase II ouverte évaluant en fonction du polymorphisme du CYP2D6, le taux de réponse biologique au traitement par tamoxifène (TAM) administré en situation pré-opératoire chez des patientes présentant un cancer du sein non métastatique RH+ - TAMEUCTR2008-007652-10-FRCentre René Gauducheau
进行中（未招募）
1 期
ESTUDIO DE FASE 2, PROSPECTIVO, ALEATORIZADO, MULTICÉNTRICO, DOBLE CIEGO, CON CONTROL ACTIVO Y DE GRUPOS PARALELOS PARA DETERMINAR LA SEGURIDAD Y ELEGIR UN RÉGIMEN TERAPÉUTICO CON CC-4047 EN MONOTERAPIA O COMBINADO CON PREDNISONA PARA ESTUDIOS POSTERIORES EN PACIENTES CON MIELOFIBROSIS CON METAPLASIA MIELOIDE.Mielofibrosis con Metaplasia Mieloide.MedDRA version: 9.1Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaEUCTR2006-004553-17-ESCelgene Corporation88